{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:27:17Z","timestamp":1779305237395,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T00:00:00Z","timestamp":1445385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00228-015-1953-5","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T02:18:46Z","timestamp":1445480326000},"page":"39-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail"],"prefix":"10.1007","volume":"72","author":[{"given":"Thu Thuy","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"B\u00e9nech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Pruvost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natacha","family":"Lenuzza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,21]]},"reference":[{"key":"1953_CR1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.clpt.6100050","volume":"81","author":"U Fuhr","year":"2007","unstructured":"Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the \u201ccocktail\u201d approach. Clin Pharmacol Ther 81:270\u2013283. doi: 10.1038\/sj.clpt.6100050","journal-title":"Clin Pharmacol Ther"},{"key":"1953_CR2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0009-9236(03)00229-7","volume":"74","author":"S Chainuvati","year":"2003","unstructured":"Chainuvati S, Nafziger AN, Leeder JS et al (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the \u201cCooperstown 5+1 cocktail\u201d. Clin Pharmacol Ther 74:437\u2013447. doi: 10.1016\/S0009-9236(03)00229-7","journal-title":"Clin Pharmacol Ther"},{"key":"1953_CR3","author":"N Lenuzza","year":"2014","unstructured":"Lenuzza N, Duval X, Nicolas G et al (2014) Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. Eur J Drug Metab Pharmacokinet. doi: 10.1007\/s13318-014-0239-0","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1953_CR4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00228-011-1174-5","volume":"68","author":"G Zadoyan","year":"2012","unstructured":"Zadoyan G, Rokitta D, Klement S et al (2012) Effect of Ginkgo biloba special extract EGb 761\u00ae on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. Eur J Clin Pharmacol 68:553\u2013560. doi: 10.1007\/s00228-011-1174-5","journal-title":"Eur J Clin Pharmacol"},{"key":"1953_CR5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1124\/dmd.112.050203","volume":"41","author":"O Doroshyenko","year":"2013","unstructured":"Doroshyenko O, Rokitta D, Zadoyan G et al (2013) Drug cocktail interaction study on the effect of the orally administered lavender oil preparation silexan on cytochrome P450 enzymes in healthy volunteers. Drug Metab Dispos 41:987\u2013993. doi: 10.1124\/dmd.112.050203","journal-title":"Drug Metab Dispos"},{"key":"1953_CR6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/SLA.0b013e31827a0e82","volume":"258","author":"S Tandra","year":"2013","unstructured":"Tandra S, Chalasani N, Jones DR et al (2013) Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann Surg 258:262\u2013269. doi: 10.1097\/SLA.0b013e31827a0e82","journal-title":"Ann Surg"},{"key":"1953_CR7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1530\/EJE-10-0764","volume":"163","author":"D Tomalik-Scharte","year":"2010","unstructured":"Tomalik-Scharte D, Maiter D, Kirchheiner J et al (2010) Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol 163:919\u2013924. doi: 10.1530\/EJE-10-0764","journal-title":"Eur J Endocrinol"},{"key":"1953_CR8","unstructured":"EMA (2012) Guideline on the investigation of drug interactions"},{"key":"1953_CR9","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/00008571-200112000-00006","volume":"11","author":"YS Lin","year":"2001","unstructured":"Lin YS, Lockwood GF, Graham MA et al (2001) In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11:781\u2013791","journal-title":"Pharmacogenetics"},{"key":"1953_CR10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clpt.2005.08.004","volume":"78","author":"HN Chaobal","year":"2005","unstructured":"Chaobal HN, Kharasch ED (2005) Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther 78:529\u2013539. doi: 10.1016\/j.clpt.2005.08.004","journal-title":"Clin Pharmacol Ther"},{"key":"1953_CR11","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/jnci\/djh298","volume":"96","author":"RHJ Mathijssen","year":"2004","unstructured":"Mathijssen RHJ, de Jong FA, van Schaik RHN et al (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585\u20131592. doi: 10.1093\/jnci\/djh298","journal-title":"J Natl Cancer Inst"},{"key":"1953_CR12","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.2042-7158.2011.01326.x","volume":"63","author":"V Perera","year":"2011","unstructured":"Perera V, Gross AS, Xu H, McLachlan AJ (2011) Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol 63:1161\u20131168. doi: 10.1111\/j.2042-7158.2011.01326.x","journal-title":"J Pharm Pharmacol"},{"key":"1953_CR13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00008571-199406000-00001","volume":"4","author":"U Fuhr","year":"1994","unstructured":"Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine\/caffeine ratio in plasma and in saliva. Pharmacogenetics 4:109\u2013116","journal-title":"Pharmacogenetics"},{"key":"1953_CR14","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.npp.1300123","volume":"28","author":"KL Shirley","year":"2003","unstructured":"Shirley KL, Hon YY, Penzak SR et al (2003) Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 28:961\u2013966. doi: 10.1038\/sj.npp.1300123","journal-title":"Neuropsychopharmacology"},{"key":"1953_CR15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-007-0288-2","volume":"63","author":"R Ghotbi","year":"2007","unstructured":"Ghotbi R, Christensen M, Roh H-K et al (2007) Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype\u2013phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63:537\u2013546. doi: 10.1007\/s00228-007-0288-2","journal-title":"Eur J Clin Pharmacol"},{"key":"1953_CR16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00228-007-0438-6","volume":"64","author":"N Djordjevic","year":"2008","unstructured":"Djordjevic N, Ghotbi R, Bertilsson L et al (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 64:381\u2013385. doi: 10.1007\/s00228-007-0438-6","journal-title":"Eur J Clin Pharmacol"},{"key":"1953_CR17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00228-012-1437-9","volume":"69","author":"SC Mueller","year":"2013","unstructured":"Mueller SC, Drewelow B (2013) Evaluation of limited sampling models for prediction of oral midazolam AUC for CYP3A phenotyping and drug interaction studies. Eur J Clin Pharmacol 69:1127\u20131134. doi: 10.1007\/s00228-012-1437-9","journal-title":"Eur J Clin Pharmacol"},{"key":"1953_CR18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/clpt.2014.83","volume":"96","author":"M Bosilkovska","year":"2014","unstructured":"Bosilkovska M, Samer CF, D\u00e9glon J et al (2014) Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther 96:349\u2013359. doi: 10.1038\/clpt.2014.83","journal-title":"Clin Pharmacol Ther"},{"key":"1953_CR19","unstructured":"Gabrielsson J, Weiner D (2001) Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 3rd edn. CRC"},{"key":"1953_CR20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","volume":"5","author":"LB Sheiner","year":"1977","unstructured":"Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445\u2013479","journal-title":"J Pharmacokinet Biopharm"},{"key":"1953_CR21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.pharmtox.40.1.67","volume":"40","author":"LB Sheiner","year":"2000","unstructured":"Sheiner LB, Steimer JL (2000) Pharmacokinetic\/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67\u201395. doi: 10.1146\/annurev.pharmtox.40.1.67","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1953_CR22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","volume":"33","author":"AF Meer Van der","year":"2011","unstructured":"Van der Meer AF, Marcus MAE, Touw DJ et al (2011) Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit 33:133\u2013146. doi: 10.1097\/FTD.0b013e31820f40f8","journal-title":"Ther Drug Monit"},{"key":"1953_CR23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF01062273","volume":"18","author":"MK al-Banna","year":"1990","unstructured":"al-Banna MK, Kelman AW, Whiting B (1990) Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 18:347\u2013360","journal-title":"J Pharmacokinet Biopharm"},{"key":"1953_CR24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF03036255","volume":"19","author":"Y Hashimoto","year":"1991","unstructured":"Hashimoto Y, Sheiner LB (1991) Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 19:333\u2013353","journal-title":"J Pharmacokinet Biopharm"},{"key":"1953_CR25","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF02353491","volume":"24","author":"EN Jonsson","year":"1996","unstructured":"Jonsson EN, Wade JR, Karlsson MO (1996) Comparison of some practical sampling strategies for population pharmacokinetic studies. J Pharmacokinet Biopharm 24:245\u2013263","journal-title":"J Pharmacokinet Biopharm"},{"key":"1953_CR26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02353788","volume":"23","author":"Y Merl\u00e9","year":"1995","unstructured":"Merl\u00e9 Y, Mentr\u00e9 F (1995) Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. J Pharmacokinet Biopharm 23:101\u2013125","journal-title":"J Pharmacokinet Biopharm"},{"key":"1953_CR27","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s11095-013-1079-3","volume":"30","author":"FP Combes","year":"2013","unstructured":"Combes FP, Retout S, Frey N, Mentr\u00e9 F (2013) Prediction of shrinkage of individual parameters using the Bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics. Pharm Res 30:2355\u20132367. doi: 10.1007\/s11095-013-1079-3","journal-title":"Pharm Res"},{"key":"1953_CR28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cmpb.2009.09.012","volume":"98","author":"C Bazzoli","year":"2010","unstructured":"Bazzoli C, Retout S, Mentr\u00e9 F (2010) Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Prog Biomed 98:55\u201365. doi: 10.1016\/j.cmpb.2009.09.012","journal-title":"Comput Methods Prog Biomed"},{"key":"1953_CR29","unstructured":"Mentr\u00e9 F, Nguyen TT, Lestini G et al (2014) PFIM 4.0: new features for optimal design in nonlinear mixed effects models using R. Abstract 3032. Meeting of the Population Approach Group in Europe. Alicante, Spain"},{"key":"1953_CR30","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/rcm.4641","volume":"24","author":"O Videau","year":"2010","unstructured":"Videau O, Delaforge M, Levi M et al (2010) Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun Mass Spectrom 24:2407\u20132419. doi: 10.1002\/rcm.4641","journal-title":"Rapid Commun Mass Spectrom"},{"key":"1953_CR31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/clpt.2010.136","volume":"88","author":"BP Smith","year":"2010","unstructured":"Smith BP, Vincent J (2010) Biostatistics and pharmacometrics: quantitative sciences to propel drug development forward. Clin Pharmacol Ther 88:141\u2013144. doi: 10.1038\/clpt.2010.136","journal-title":"Clin Pharmacol Ther"},{"key":"1953_CR32","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.csda.2004.07.002","volume":"49","author":"E Kuhn","year":"2005","unstructured":"Kuhn E, Lavielle M (2005) Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 49:1020\u20131038. doi: 10.1016\/j.csda.2004.07.002","journal-title":"Comput Stat Data Anal"},{"key":"1953_CR33","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.csda.2006.05.007","volume":"51","author":"A Samson","year":"2006","unstructured":"Samson A, Lavielle M, Mentr\u00e9 F (2006) Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model. Comput Stat Data Anal 51:1562\u20131574. doi: 10.1016\/j.csda.2006.05.007","journal-title":"Comput Stat Data Anal"},{"key":"1953_CR34","doi-asserted-by":"crossref","unstructured":"Bonate PL, Howard DR (2011) Pharmacokinetics in drug development: advances and applications. Springer Science & Business Media","DOI":"10.1007\/978-1-4419-7937-7"},{"key":"1953_CR35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.phrs.2011.01.009","volume":"63","author":"F Saint-Marcoux","year":"2011","unstructured":"Saint-Marcoux F, Guigonis V, Decramer S et al (2011) Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacol Res 63:423\u2013431. doi: 10.1016\/j.phrs.2011.01.009","journal-title":"Pharmacol Res"},{"key":"1953_CR36","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503\u2013512","journal-title":"J Pharmacokinet Biopharm"},{"key":"1953_CR37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40262-013-0115-0","volume":"53","author":"M Donzelli","year":"2014","unstructured":"Donzelli M, Derungs A, Serratore M-G et al (2014) The Basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet 53:271\u2013282. doi: 10.1007\/s40262-013-0115-0","journal-title":"Clin Pharmacokinet"},{"key":"1953_CR38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10928-008-9104-6","volume":"35","author":"M Chenel","year":"2008","unstructured":"Chenel M, Bouzom F, Aarons L, Ogungbenro K (2008) Drug\u2013drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes. J Pharmacokinet Pharmacodyn 35:635\u2013659. doi: 10.1007\/s10928-008-9104-6","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1953_CR39","first-page":"E758","volume":"274","author":"A Rostami-Hodjegan","year":"1998","unstructured":"Rostami-Hodjegan A, Peacey SR, George E et al (1998) Population-based modeling to demonstrate extrapancreatic effects of tolbutamide. Am J Physiol 274:E758\u2013E771","journal-title":"Am J Physiol"},{"key":"1953_CR40","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1124\/dmd.113.053074","volume":"41","author":"V Perera","year":"2013","unstructured":"Perera V, Gross AS, Forrest A et al (2013) A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. Drug Metab Dispos 41:1957\u20131966. doi: 10.1124\/dmd.113.053074","journal-title":"Drug Metab Dispos"},{"key":"1953_CR41","first-page":"493","volume":"25","author":"M Silvasti","year":"1987","unstructured":"Silvasti M, Karttunen P, Tukiainen H et al (1987) Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers. Int J Clin Pharmacol Ther Toxicol 25:493\u2013497","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"1953_CR42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1365-2125.2009.03548.x","volume":"68","author":"S Turpault","year":"2009","unstructured":"Turpault S, Brian W, Van Horn R et al (2009) Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 68:928\u2013935. doi: 10.1111\/j.1365-2125.2009.03548.x","journal-title":"Br J Clin Pharmacol"},{"key":"1953_CR43","first-page":"347","volume":"39","author":"AC Atkinson","year":"1997","unstructured":"Atkinson AC, Bogacka B (1997) Compound D- and D s-optimum designs for determining the order of a chemical reaction. Technometrics 39:347. doi: 10.2307\/1271499","journal-title":"Technometrics"},{"key":"1953_CR44","doi-asserted-by":"crossref","unstructured":"Holger Dette TH-L (2009) A geometric characterization of $c$-optimal designs for heteroscedastic regression. doi: 10.1214\/09-AOS708","DOI":"10.1214\/09-AOS708"},{"key":"1953_CR45","unstructured":"Nguyen TT, B\u00e9nech H, Delaforge M et al (2014) Optimal sampling times for pharmacokinetic modelling of a cocktail of phenotyping drugs. Population Optimum Design of Experiments Workshop. Basel. Switzerland"},{"key":"1953_CR46","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pst.1509","volume":"11","author":"LK Foo","year":"2012","unstructured":"Foo LK, McGree J, Duffull S (2012) A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies. Pharm Stat 11:325\u2013333. doi: 10.1002\/pst.1509","journal-title":"Pharm Stat"},{"key":"1953_CR47","volume":"1","author":"PH Graaf Van der","year":"2012","unstructured":"Van der Graaf PH (2012) CPT: pharmacometrics and systems pharmacology. CPT Pharmacomet Syst Pharmacol 1, e8. doi: 10.1038\/psp.2012.8","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1953_CR48","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.19","volume":"2","author":"F Mentr\u00e9","year":"2013","unstructured":"Mentr\u00e9 F, Chenel M, Comets E et al (2013) Current use and developments needed for optimal design in pharmacometrics: a study performed among DDMoRe\u2019s European Federation of Pharmaceutical Industries and Associations Members. CPT Pharmacometrics Syst Pharmacol 2, e46. doi: 10.1038\/psp.2013.19","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1953-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-1953-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-1953-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T21:17:40Z","timestamp":1653340660000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-1953-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,21]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["1953"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-1953-5","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,21]]}}}